Logo image of TBIO

TELESIS BIO INC (TBIO) Stock Fundamental Analysis

NASDAQ:TBIO - Nasdaq - US1920032000 - Common Stock - Currency: USD

3.23  -0.76 (-19.05%)

After market: 2.85 -0.38 (-11.76%)

Fundamental Rating

1

Taking everything into account, TBIO scores 1 out of 10 in our fundamental rating. TBIO was compared to 57 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of TBIO have multiple concerns. TBIO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TBIO has reported negative net income.
In the past year TBIO has reported a negative cash flow from operations.
TBIO had negative earnings in each of the past 5 years.
In the past 5 years TBIO always reported negative operating cash flow.
TBIO Yearly Net Income VS EBIT VS OCF VS FCFTBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of TBIO (-98.37%) is worse than 92.98% of its industry peers.
TBIO has a worse Return On Equity (-521.49%) than 91.23% of its industry peers.
Industry RankSector Rank
ROA -98.37%
ROE -521.49%
ROIC N/A
ROA(3y)-54.24%
ROA(5y)-50.23%
ROE(3y)-104.32%
ROE(5y)-94.65%
ROIC(3y)N/A
ROIC(5y)N/A
TBIO Yearly ROA, ROE, ROICTBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

TBIO's Gross Margin of 47.88% is in line compared to the rest of the industry. TBIO outperforms 54.39% of its industry peers.
TBIO's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for TBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.78%
GM growth 5YN/A
TBIO Yearly Profit, Operating, Gross MarginsTBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

TBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TBIO has been increased compared to 1 year ago.
The debt/assets ratio for TBIO has been reduced compared to a year ago.
TBIO Yearly Shares OutstandingTBIO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 500K 1M 1.5M
TBIO Yearly Total Debt VS Total AssetsTBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

TBIO has an Altman-Z score of -6.48. This is a bad value and indicates that TBIO is not financially healthy and even has some risk of bankruptcy.
TBIO has a worse Altman-Z score (-6.48) than 91.23% of its industry peers.
A Debt/Equity ratio of 0.54 indicates that TBIO is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.54, TBIO is not doing good in the industry: 63.16% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Altman-Z -6.48
ROIC/WACCN/A
WACC14.42%
TBIO Yearly LT Debt VS Equity VS FCFTBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

TBIO has a Current Ratio of 1.89. This is a normal value and indicates that TBIO is financially healthy and should not expect problems in meeting its short term obligations.
TBIO has a worse Current ratio (1.89) than 61.40% of its industry peers.
TBIO has a Quick Ratio of 1.72. This is a normal value and indicates that TBIO is financially healthy and should not expect problems in meeting its short term obligations.
TBIO has a Quick ratio (1.72) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.72
TBIO Yearly Current Assets VS Current LiabilitesTBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for TBIO have decreased strongly by -1673.33% in the last year.
The Revenue for TBIO has decreased by -43.65% in the past year. This is quite bad
TBIO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 61.13% yearly.
EPS 1Y (TTM)-1673.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2621.43%
Revenue 1Y (TTM)-43.65%
Revenue growth 3Y61.13%
Revenue growth 5YN/A
Sales Q2Q%-82.09%

3.2 Future

Based on estimates for the next years, TBIO will show a very negative growth in Earnings Per Share. The EPS will decrease by -29.72% on average per year.
TBIO is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -40.92% yearly.
EPS Next Y-122.26%
EPS Next 2Y-29.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-66.55%
Revenue Next 2Y-40.92%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TBIO Yearly Revenue VS EstimatesTBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
TBIO Yearly EPS VS EstimatesTBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TBIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TBIO Price Earnings VS Forward Price EarningsTBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TBIO Per share dataTBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

A cheap valuation may be justified as TBIO's earnings are expected to decrease with -29.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.72%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TELESIS BIO INC

NASDAQ:TBIO (9/27/2024, 8:22:41 PM)

After market: 2.85 -0.38 (-11.76%)

3.23

-0.76 (-19.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-07 2024-08-07/amc
Earnings (Next)11-11 2024-11-11/amc
Inst Owners2.63%
Inst Owner Change0%
Ins Owners5195.21%
Ins Owner Change0%
Market Cap5.72M
Analysts82.86
Price Target4.08 (26.32%)
Short Float %0.03%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-58.05%
Min EPS beat(2)-85.37%
Max EPS beat(2)-30.72%
EPS beat(4)0
Avg EPS beat(4)-35.22%
Min EPS beat(4)-85.37%
Max EPS beat(4)-2.5%
EPS beat(8)4
Avg EPS beat(8)-9.5%
EPS beat(12)5
Avg EPS beat(12)-9.14%
EPS beat(16)8
Avg EPS beat(16)19.54%
Revenue beat(2)0
Avg Revenue beat(2)-63.87%
Min Revenue beat(2)-76.62%
Max Revenue beat(2)-51.12%
Revenue beat(4)0
Avg Revenue beat(4)-39.08%
Min Revenue beat(4)-76.62%
Max Revenue beat(4)-2.28%
Revenue beat(8)2
Avg Revenue beat(8)-15.2%
Revenue beat(12)4
Avg Revenue beat(12)-9.56%
Revenue beat(16)5
Avg Revenue beat(16)-24.1%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-101.22%
EPS NY rev (1m)0%
EPS NY rev (3m)-64.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-74.68%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-65.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 0.57
P/tB 1
EV/EBITDA N/A
EPS(TTM)-23.94
EYN/A
EPS(NY)-19.27
Fwd EYN/A
FCF(TTM)-12.84
FCFYN/A
OCF(TTM)-12.31
OCFYN/A
SpS9.9
BVpS5.62
TBVpS3.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -98.37%
ROE -521.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.88%
FCFM N/A
ROA(3y)-54.24%
ROA(5y)-50.23%
ROE(3y)-104.32%
ROE(5y)-94.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.78%
GM growth 5YN/A
F-Score4
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.13%
Cap/Sales 5.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.72
Altman-Z -6.48
F-Score4
WACC14.42%
ROIC/WACCN/A
Cap/Depr(3y)185.64%
Cap/Depr(5y)117.94%
Cap/Sales(3y)13.42%
Cap/Sales(5y)9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1673.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2621.43%
EPS Next Y-122.26%
EPS Next 2Y-29.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-43.65%
Revenue growth 3Y61.13%
Revenue growth 5YN/A
Sales Q2Q%-82.09%
Revenue Next Year-66.55%
Revenue Next 2Y-40.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.86%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.42%
OCF growth 3YN/A
OCF growth 5YN/A